II CANCER CELL SIGNALING PATHWAYS CONFERENCE

Transcription

1 II CANCER CELL SIGNALING PATHWAYS CONFERENCE AN IN DEPTH LOOK AT LUNG, MELANOMA, GLIOBLASTOMA, BREAST, HEAD & NECK SQUAMOUS CELL CANCERS Fundació Institut d Investigació en Ciències de la Salut Germans Trias i Pujol, edifici Muntanya Seminar Room, Badalona, - July 6th, 2017 Organized by: Rafael Rosell, Imane Chaib, Maria Gonzalez-Cao and Niki Karachaliou Graphical Abstract Highlights: Co-activation of receptor tyrosine kinases and non-receptor tyrosine kinases is a common feature in cancer. Cross-talk between different signaling pathways is the basis for polytherapy in several tumors. Rewiring of cell signals occurs as a response to therapy.

2 PROGRAM 08:30: Welcome 8:45 9:00: Cell maps for gauging the evolution of cancer - Rafael Rosell, Cancer Biology & Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Badalona, Spain SESSION I Chairpersons: Miguel Angel Molina and Niki Karachaliou 9:00 9:30: Signal transducer and activator of transcription 3 (STAT3) and YES-associated protein 1 (YAP1) signaling in EGFR mutant non-small-cell lung cancer limits targeted therapy response Targeted pathway inhibitors (western blots and in vitro viability assays) - Imane Chaib, Cancer Biology & Precision Medicine Program, Germans Trias i Pujol Health Sciences Institute, Badalona, Spain Mouse models and quantitative RT- PCR in EGFR mutant NSCLC patients Quiron-Dexeus Hospital, 9:30-9:45: Discussion 9:45 10:15: The missing view in cancer biology and the contribution of patients families Lars Soraas, Oslo, Norway Jo Monsen, Oslo, Norway 10:15 10:30: The view of the clinical investigator Nuno Gil, Champalimaud Cancer Center, Lisbon, Portugal 10:30 10:45: Coffee Break SESSION II Chairpersons: Niki Karachaliou and Miguel Angel Molina 10:45 12:15: Co-activation of receptor tyrosine and non-receptor tyrosine kinases in EGFR mutant NSCLC Phospho-receptor kinase antibody arrays and immunofluorescence - Jordi Berenguer, Coyote Research Group, Pangaea Oncology, Quiron-Dexeus Hospital, Quantitative RT-PCR and colony formation assays - Jill Bracht, Coyote Research Group, Pangaea Oncology, Quiron-Dexeus Hospital,

3 In vitro viability assays to audit TPX-0005, cabozantinib, dasatinib and HP90i - Imane Chaib, Cancer Biology & Precision Medicine Program, Germans Trias i Pujol Health Sciences Institute, Badalona, Spain - Jordi Codony, Coyote Research Group, Pangaea Oncology, Quiron-Dexeus Hospital, - Jill Bracht, Coyote Research Group, Pangaea Oncology, Quiron-Dexeus Hospital, Concomitant or alternate treatment with EGFR TKIs - Jordi Berenguer, Coyote Research Group, Pangaea Oncology, Quiron-Dexeus Hospital, Differential sensitivity with gefitinib, osimertinib, afatinib and dacomitinib - Marta Horcas, Cancer Biology & Precision Medicine Program, Germans Trias i Pujol Health Sciences Institute, Badalona, Spain Mouse models Quiron-Dexeus Hospital, Phase I clinical trial with osimertinib (or other EGFR TKIs) plus TPX-0005 in first line EGFR mutant NSCLC Quiron-Dexeus Hospital, 12:15 12:30: Discussion SESSION III Chairpersons: Imane Chaib, Jose Luis Ramirez 12:30 12:45: Squamous cell carcinoma of the lung - Alberto Verlicchi, SC Oncologia. Fondazione IRCCS Policlinico San Matteo, Pavia, Italy 12:45 13:15: Squamous cell carcinoma of head and neck - Rafael Rosell, Cancer Biology & Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Badalona, Spain 13:15 13:30: RESPONSE project: Exploiting chromatin for drug response - Marcus Buschbeck, Josep Carreras Leukaemia Research Institute, Germans Trias i Pujol Health Sciences Institute, Badalona, Spain 13:30 13:45: Relevance of PTPRT mutations and STAT3 signaling - Jose Luis Ramirez, Cancer Biology & Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Badalona, Spain 13:45 14:00: Discussion and Lunch

4 SESSION IV Chairpersons: Carles Codony, Maria de los Llanos Gil 14:00 14:15: KRAS mutant NSCLC Tracking signaling pathways - Chiara Lazzari, Dept. of Oncology, Division of Experimental Medicine, IRCCS San Raffaele, Milan, Italy In vitro viability assays to audit different targeted combinations - Carles Codony, Coyote Research Group, Pangaea Oncology, Quirón-Dexeus Hospital, 14:15 14:30: Discussion SESSION V Chairpersons: Luis Montuenga, Santiago Ramon y Cajal 14:30 14:45: New insights in MNKs Santiago Ramón y Cajal, Pathology Dept. Vall d Hebron University Hospital, 14:45 15:00: The relevance of paracrine cross-talk in lung carcinogenesis Luis M. Montuenga, Center for Applied Medical Research, CIMA, Pamplona, Spain 15:00 15:15: Discussion 15:15 15:30: Interferon gamma signaling pathway and response to immune checkpoint inhibitors in NSCLC and melanoma - Maria Gonzalez Cao, IOR, Quiron-Dexeus Hospital, 15:30 15:45: Intratumor heterogeneity in small-cell-lung cancer and NOTCH signaling Quiron-Dexeus Hospital,

5 SESSION VI Chairpersons: Andres Felipe Cardona, Miguel Angel Molina 15:45 16:00: AXL in triple negative breast cancer - Libero Santarpia, Coyote Research Group, Pangaea Oncology, Quiron-Dexeus Hospital, 16:00 16:15: Discussion 16:15 16:30: EGFR mutations in early resected NSCLC - Masaoki Ito, Coyote Research Group, Pangaea Oncology, Quiron-Dexeus Hospital, Barcelona, Spain - 16:30 16:45: EGFR mutations in Latin America - Andres Felipe Cardona, Clinica del Country, Bogota, Colombia 16:45 17:00: Discussion/Coffee break SESSION VII Chairpersons: Bartomeu Massuti, Santiago Viteri 17:00 17:15: SLCG clinical trials - Bartomeu Massuti, Hospital General de Alicante, Spain 17:15 17:30: Improving clinical trials - Alejandro Martinez Bueno, IOR, Quiron-Dexeus Hospital, 17:30 17:45: Moving forward with clinical trials - François Riva, MedSir, 17:45 18:00: Immune checkpoint inhibitor therapy in HIV positive cancer patients - Maria Gonzalez Cao, IOR, Quiron-Dexeus Hospital, 18:00 18:30: Round Table: Views on amalgamating research for improving cancer care - Chairs: Bartomeu Massuti and Santiago Viteri - Nuno Gil, Lars Soraas, Jo Monsen, François Riva, Alejandro Martinez Bueno, Niki Karachaliou, Maria Gonzalez Cao, Andres Felipe Cardona, Masaoki Ito 18:30: CLOSING REMARKS

6 Cancer Biology and Precision Medicine Laboratory Supporting companies

7 For FREE REGISTRATION, indicating your full name and affiliation For more general information, here is the meeting web: How to get to the Fundació Institut d Investigació en Ciències de la Salut Germans Trias i Pujol By car / taxi: We are 20 minutes from the center of the city and the most convenient way to arrive is by car or taxi. We are close to the Hospital which can serve as a good point of reference: Hospital Universitari Germans Trias I Pujol (Popularly known as Can Rutí) GPS: N E From Barcelona take B20 (Rondas and Nus de la Trinitat) in direction Mataró. The hospital is well signed from the exit 21 (Badalona Centre) of the B20. With the collaboration of Harvey Evans, Lourdes Franquet and Stephanie Davis